Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Naomi_Judd
gptkb:hepatitis_C_virus |
| gptkbp:advises |
recommend testing and treatment
|
| gptkbp:caused_by |
gptkb:hepatitis_C_virus
|
| gptkbp:clinical_trial |
ongoing for new therapies
|
| gptkbp:cultural_practices |
associated with drug use
|
| gptkbp:disease_resistance |
leading cause of liver transplants
|
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:education |
important for management
|
| gptkbp:film_score |
used to evaluate liver health
|
| gptkbp:genetic_diversity |
most common genotype in the US
common in South Asia six major genotypes |
| gptkbp:healthcare |
can be significant for chronic management
significant global health issue |
| https://www.w3.org/2000/01/rdf-schema#label |
hepatitis C
|
| gptkbp:is_a_resource_for |
available for support and information
|
| gptkbp:is_adopted_by |
possible for end-stage liver disease
|
| gptkbp:is_popular_in |
approximately 71 million people infected
|
| gptkbp:is_protected_by |
screening blood products
avoid sharing needles |
| gptkbp:is_vulnerable_to |
no vaccine available
|
| gptkbp:metabolism |
used to assess liver damage
|
| gptkbp:provides_information_on |
varies by country
|
| gptkbp:public_awareness |
aim to reduce stigma
|
| gptkbp:research |
ongoing for vaccine development
|
| gptkbp:risk_factor |
intravenous drug use
blood transfusions before 1992 healthcare exposure increases with chronic infection tattooing with unsterile equipment |
| gptkbp:scholarships |
important for affected individuals
available for treatment adherence |
| gptkbp:screenings |
high-risk populations
baby boomers |
| gptkbp:social_responsibility |
gptkb:healthcare_organization
gptkb:HIV blood test often asymptomatic HCVRNA test can lead to liver cancer can lead to liver cirrhosis anti-HCV antibody test may resolve spontaneously can lead to liver failure requires long-term management |
| gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice |
| gptkbp:transmission |
blood-to-blood contact
|
| gptkbp:treatment |
gptkb:glecaprevir/pibrentasvir
gptkb:ledipasvir gptkb:sofosbuvir gptkb:velpatasvir antiviral medications over 95% with direct-acting antivirals |